Research ArticleClinical Studies

An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer

CARSTEN NIEDER and KRISTIAN S. IMINGEN
In Vivo March 2021, 35 (2) 955-958; DOI: https://doi.org/10.21873/invivo.12336

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Actuarial overall survival (Kaplan–Meier curves) for patients without distant metastases treated to high radiation doses such as 15 fractions of 2.8 Gy. Median survival was 12 months in 29 patients with a heart dose below the median (26 Gy) and 15 months in 29 patients with a heart dose above the median (p>0.1).

Tables

  • Table I.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer
CARSTEN NIEDER, KRISTIAN S. IMINGEN
In Vivo Mar 2021, 35 (2) 955-958; DOI: 10.21873/invivo.12336
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords